2-Oct-24

Fluorescent Antibody-Based Detection and Ultrastructural Analysis of *Streptococcus pneumoniae* in Human Sputum

Ana G. Jop Vidal[1,#], Meg Francis[1,#], Maneesha Chitanvis[4], Ithiel J. Frame[3,*], Poonam Sharma[3], Patricio Vidal[1], Claudio F. Lanata[5], Carlos Grijalva[6], William Daley[3], and Jorge E. Vidal[1,2]

[1]Department of Cell and Molecular Biology, [2]Center for Immunology and Microbial Research, [3]Department of Pathology, University of Mississippi Medical Center, Jackson MS; [4]Rollins School of Public Health; Emory University, Atlanta GA; [5]Instituto de Investigacion Nutricional; Lima, Peru; [6]Department of Health Policy, Vanderbilt University Medical Center, Nashville, TN

[#]These authors contributed equally to the manuscript

*Current affiliation: Quest Diagnostics, Lewisville, TX

Running title: Spn-FLUO for pneumococcal detection in sputum

Address correspondence to:

Jorge E. Vidal, PhD. Department of Cell and Molecular Biology, University of Mississippi Medical Center. 2500 North State St, Jackson MS 39216. Email: jvidal@umc.edu

Abstract

Background: Pneumococcal pneumonia continues to be a significant global health burden, affecting both children and adults. Traditional diagnostic methods for sputum analysis remain challenging. The objective of this study was twofold: to develop a rapid and easy-to-perform assay for the identification of *Streptococcus pneumoniae* (Spn) directly in sputum specimens using fluorescence microscopy, and to characterize with high-resolution confocal microscopy the ultrastructure of pneumococci residing in human sputum. ***Methods:*** We fluorescently labeled antibodies against the pneumococcal capsule (Spn-FLUO). The specificity and sensitivity of Spn-FLUO for detecting Spn was evaluated *in vitro* and *in vivo* using mouse models of carriage and disease, human nasopharyngeal specimens, and sputum from patients with pneumococcal pneumonia. Spn was confirmed in the specimens using culture and a species-specific qPCR assays. Confocal microscopy and Imaris software analysis were utilized to resolve the ultrastructure of pneumococci in human sputum. ***Results:*** Compared with cultures and qPCR, Spn-FLUO demonstrated high sensitivity (78-96%) in nasopharyngeal samples from mice and humans. The limit of detection (LOD) in nasopharyngeal samples was $\geq 1.6 \times 10^4$ GenEq/ml. The specificity in human nasopharyngeal specimens was 100%. In lung specimens from mice infected with pneumococci, Spn-FLUO reached 100% sensitivity with a LOD of $\geq 1.39 \times 10^4$ GenEq/ml. In human sputum, the sensitivity for detecting Spn was 92.7% with a LOD of 3.6×10^3 GenEq/ml. Ultrastructural studies revealed that pneumococci are expectorated as large aggregates with a median size of 1336 μm^2. ***Conclusions:*** Spn-FLUO is a rapid and sensitive assay for detecting Spn in human sputum within 30 min. The study highlights that most pneumococci form aggregates in human sputum.

Background

Streptococcus pneumoniae (Spn) strains infect the lungs causing pneumococcal pneumonia, a common community-acquired pneumonia (CAP) that causes over a million deaths annually worldwide[1]. Pneumococcal pneumonia is an acute bacterial infection of the pulmonary parenchyma caused by colonization of the lung and subsequent, or concurrent, invasion of pneumococci into the respiratory epithelium[2, 3]. Invasion of bronchi and terminal bronchiole leads pneumococci to reach respiratory bronchiole, alveolar ducts, and alveoli, where pneumococci have access to the alveolar-capillary network, a large surface area containing ~300 billion of blood capillaries and where the exchange of CO_2 by O_2 occurs.

Spn strains encompass over 100 capsular types; the capsule is a target of pneumococcal vaccines that have saved millions since their licensure[4]. The capsular polysaccharide is negatively charged, enabling pneumococci to colonize the lungs by evading entrapment by mucus secreted in the lumen of bronchi and terminal bronchiole[2]. The capsule also acts as an anti-phagocytic factor by blocking complement deposition[2, 5, 6, 7]. Consequently, expression of the pneumococcal capsule is maximized during pneumococcal pneumonia and it was utilized in this study to identify the presence of Spn in clinical specimens.

The diagnosis of pneumococcal pneumonia is based on symptoms and suggestive radiographic findings[8, 9]. Diagnostic testing to determine pneumococcal pneumonia is optional for non-hospitalized patients, while those requiring admission should undergo blood cultures, respiratory cultures, and Gram staining of good-quality sputum. If the disease is severe, a urinary antigen test may also be considered[8]. However, cultures have poor sensitivity and can

66 take at least 24 h to yield results. Moreover, the urinary antigen test for identifying
67 pneumococcal pneumonia has limited sensitivity and specificity[8].

68 Pneumonia multiplex (m)PCR panels have demonstrated superior performance in
69 detecting respiratory pathogens, including pneumococcal strains. mPCR panels offer improved
70 specificity and turnaround time compared to traditional methods[10]. Other molecular assays
71 include real-time PCR methods targeting a number of species-specific genes, or gene
72 sequences, such as the gene encoding the autolysin *lytA*[11, 12], the pneumolysin *ply*[12] gene, the
73 permease gene *piaB* of the iron transporter PiaABC[13] or a putative transcriptional regulator
74 SP2020[14]. These PCR assays typically exhibit high sensitivity and specificity (>90%), and
75 depending on the platform, real-time assays can deliver results within 3-4 h.

76 Prompt and accurate identification of pneumococcal pneumonia as the etiology is
77 crucial for tailoring antibiotic management to a specific patient, which is paramount to
78 preventing complications and mortality[8, 15]. Early administration of antibiotic therapy has been
79 demonstrated to improve short-term mortality rates in both human patients and animal
80 models of pneumococcal disease[16, 17]. Antibiotic therapy for community-acquired pneumonia
81 (CAP) is typically initiated empirically within 1-2 h of presentation to a healthcare facility, prior
82 to the identification of the causative pathogen[16]. However, the indiscriminate use of empirically
83 prescribed antibiotics has contributed to a significant increase in antimicrobial resistance rates,
84 particularly in certain geographical regions. For example, in some areas, over 70% of Spn strains
85 isolated from pneumococcal pneumonia cases are resistant to first-line macrolide antibiotics[18,
86 19].

Addressing the global burden of antibiotic resistance requires multifaceted efforts, including ensuring equitable access to, and developing innovative, diagnostics. In this study, we fluorescently labeled antibodies against the pneumococcal capsule, hereafter referred to as Spn-FLUO, and evaluated their performance in detecting pneumococcal strains within 30 min. Given the capsule's high expression during pneumococcal disease, we hypothesized that antibodies targeting the capsule would enhance the rapid detection of strains in lower airway specimens. We systematically tested Spn-FLUO to detect Spn strains grown *in vitro*, as well as strains colonizing the upper and lower airways of mice in murine models of carriage and disease. Additionally, we assessed the efficacy of Spn-FLUO in detecting Spn strains colonizing the nasopharynx of children. We evaluated the diagnostic performance of Spn-FLUO in identifying pneumococcal pneumonia as the etiology in specimens collected from patients with pneumococcal pneumonia. Results were obtained within 30 min of sample collection.

Given the distinctive characteristics of the pneumococci observed in the sputum, we conducted additional ultrastructural studies using high-resolution laser scanning confocal microscopy and advanced image analysis. Consequently, we present novel insights into the ultrastructure of pneumococcal aggregates formed in human sputum.

Methods

Bacterial strains, culture media, and antibiotics. Spn reference strains and mutants used in the present study were: TIGR4[20], SPJV41[21, 22], D39[23], EF3030[24], S19F 4924[25] and S6B 8655[26]. Strains were routinely cultured on blood agar plates (BAP), or grown in Todd Hewitt broth containing 0.5% (w/v) yeast extract (THY), at 37°C with a 5% CO_2 atmosphere. Where indicated,

streptomycin (Str, 200 µg/ml), trimethoprim (Tmp, 10 µg/ml), tetracycline (Tet, 1 µg/ml), or/and erythromycin (Ery, 1 µg/ml) was added to BAP. All antibiotics were purchased from Millipore-Sigma Sigma-Aldrich.

Preparation of inocula. The inoculum was prepared as previously described[27]. Briefly, bacteria were inoculated on blood agar plates (BAP) and incubated overnight at 37°C in a 5% CO_2 atmosphere. Bacteria were then harvested from plates by PBS washes and this suspension was used to inoculate THY or cell cultures, that was brought to a final OD_{600} of ~0.1. This suspension contained ~$5.15x10^8$ cfu/ml as verified by serial dilution and platting of aliquots of the suspension.

Cell cultures. Human pharyngeal Detroit 562 cells (ATCC CCL-138) were cultured in Eagle's minimum essential medium (MEM) (Gibco) supplemented with non-heat-inactivated 10% fetal bovine serum (FBS) from R&D systems, 1% nonessential amino acids (Gibco), 1% glutamine (Gibco), penicillin (100 U/ml), and streptomycin (100 µg/ml), and the pH was buffered with HEPES (10 mM) (Gibco). Cells were harvested with 0.25% trypsin (Gibco), resuspended in the cell culture medium, and incubated at 37°C in a 5% CO_2 humidified atmosphere.

Fluorescent labeling of anti-capsule antibodies. Antibodies were purchased from the Staten Serum Institute (Denmark). The following antibodies were used throughout this study: Omni antiserum (recognizes 92 serotypes), type serum 2, type serum 4, group serum 6, and group serum 19. Serum was depleted of proteins less than 100 kDa using an Amicon Ultra-100K centrifugal filter (Millipore-Sigma), washed three times with PBS. Proteins were quantified using Bradford reagent, and 1 mg of the antibodies was labeled with either Alexa-488 or Alexa-555 following the manufacturer's recommendations (Molecular Probes). After purification by size

exclusion chromatography (≥40 kDa), collected fractions were assessed for reactivity against the specific serotype, serogroup, or several serotypes for the Omni antiserum. Proteins were quantified from reactive fractions using the Bradford assay, and antisera were stored at 4°C for short-term or -20°C for long-term storage. Labeled antibodies stored at 4°C remained reactive for up to three months, while those frozen have been effective in labeling bacteria for over three years. For the sake of simplicity, the fluorescently labeled Omni antiserum is referred to as Spn-FLUO throughout this manuscript.

***In vitro* imaging of pneumococci.** Pneumococci were inoculated into 8-well glass slides (Lab-Tek®) and incubated for 4 h at 37°C in a 5% CO_2 atmosphere. Some slides contained cultures of Detroit 562 cells (ATCC CCL-198) grown to confluence, typically 7 days post seeding. Pneumococci attached to the glass substratum or human cells were then washed twice with PBS and fixed with 2% PFA for 15 min at room temperature. After removing the 2% PFA, the bacteria were washed with PBS and blocked with 2% bovine serum albumin (BSA) for 1 h at 37°C. The pneumococci were then incubated with the specified labeled antibodies (~20 µg/ml) for 1 h at room temperature. The stained preparations were subsequently washed twice with PBS and mounted with ProLong Diamond Antifade Mountant with DAPI (Molecular Probes). In some preparations, DAPI was replaced with TO-PRO-3 (1 µM), a carbocyanine monomer nucleic acid stain (Molecular Probes). Fluorescence images were acquired using an upright, epi-fluorescence Nikon Ni-U Research Microscope equipped with a Nikon DS-Qi2 sCMOS Camera system. Confocal images were obtained using a Nikon C2 laser scanning confocal microscopy system, and the micrographs were analyzed with ImageJ version 1.49k (National Institutes of Health, USA) or Imaris software (Bitplane).

Mouse models of pneumococcal nasopharyngeal carriage and disease. Inbred 6-7 week-old C57BL/6 mice -pneumococcal carriage-, or 4-5 week-old Balb/c mice -pneumococcal pneumonia- model (Charles River Laboratories) were anesthetized with 5% isoflurane (vol/vol) in oxygen (2 liters/min) administered via an RC2 calibrated vaporizer (VetEquip Inc) and then infected with ~$1x10^5$ CFU of strain Spn EF3030 (carriage model) or ~$1x10^8$ cfu of TIGR4 or SPJV41 (pneumonia model). The animals were weighed daily, and their behavior and appearance were monitored twice daily for up to four days. Mice in the pneumonia model were euthanized when they lost ≥20% of their body weight, compared to their body weight before infection, or when mice were non-responsive to manual stimulation, and/or if they show signs of illness such as ruffled fur, intermittent hunching, and exhibiting respiratory distress. Mice were then euthanized, and the upper airways, including nasopharyngeal tissue or the lungs, were aseptically collected, placed in THY with 10% glycerol and immediately homogenized. For fluorescence staining (explained below), the nasopharynx from some mice was collected and fixed with 10% PFA. The specimens were then stored at -80°C. This aliquot was used for bacterial counts and detection with labeled antibodies. To obtain bacterial counts, the homogenized tissue was serially diluted in PBS and plated onto BAP with gentamicin. The Institutional Animal Care and Use Committee (IACUC) at the University of Mississippi Medical Center approved the protocol used in this study (1584), overseeing the welfare, well-being, and proper care of all mice utilized in this study. All mouse experiments followed the guidelines outlined in the National Science Foundation Animal Welfare Act (AWA).

Fluorescence staining of nasopharyngeal tissue. The PFA-fixed nasopharynxes were paraffin-embedded, sectioned (~5 µm), mounted on a slide and deparaffinized. Tissues were washed

three times with PBS and the preparations were blocked with 2% bovine serum albumin (BSA) for 1 h at room temperature. These preparations were then incubated for 1 h with serogroup-specific (S19) polyclonal antibody (Statens Serum Institute, Denmark) (20 µg/ml) that had been previously labeled with Alexa-555 (Molecular Probes). Stained tissues were finally washed three times with PBS, air dried and then mounted with ProLong Diamond Antifade mounting medium containing DAPI (Molecular Probes). Confocal micrographs were obtained using a Nikon C2 laser scanning confocal microscopy system and analyzed using the Imaris software (Bitplane).

Specimens from Humans with Pneumococcal Pneumonia. Human specimens, including sputum and bronchoalveolar lavages from de-identified patients with microbiologically and radiologically confirmed pneumococcal pneumonia, were utilized in this study. Institutional Review Board (IRB) exemption was obtained for the use of these de-identified specimens. When available, the age of the patients ranged from 19 months through 60 years. The specimens were collected according to institutional guidelines by the University of Mississippi Medical Center's clinical laboratory and stored at -80°C until processed. As part of the microbiological diagnostics, the pathology laboratory at UMMC isolated a Spn strain from each specimen. Additionally, the Spn etiology was confirmed by *lytA*-based real-time PCR, as detailed[28, 29] and briefly described below.

Human nasopharyngeal specimens. Human nasopharyngeal specimens (N=50) utilized in the current study had been collected from Peruvian children and processed for pneumococcal detection and quantification by qPCR and culture in previous studies[30, 31]. Children enrolled in the mentioned studies were aged 0-3 years of age; details on the study population have been published elsewhere[31, 32, 33]. De-identified specimens were processed at Emory University,

obtaining IRB exemption. Briefly, these nasopharyngeal samples were collected following WHO recommendations[34] with a deep NP swab, using rayon polyester swabs and were immediately placed in 2.0 ml cryogenic vials with 1 ml of transport medium, a mixture containing skim milk-tryptone-glucose-glycerin (STGG) and then stored at -80°C[35].

Identification of pneumococcus using Spn-FLUO in mouse tissue or human specimens. Specimens were thawed on ice and an aliquot (10 µl) of each specimen was immediately mixed with Spn-FLUO (50 µg/ml) and incubated for 10 min at room temperature in the dark. Five µl of this suspension was dropped onto a microscope slide and covered with a coverslip. The stained sample was analyzed within five minutes using an upright, epi-fluorescence Nikon Ni-U Research Microscope equipped with a Nikon DS-Qi2 sCMOS Camera system. We first situated the specimen in the correct optical plane (i.e., visualizing cells, tissue, and/or bacteria) with the 60x objective and a bright light source. The slides were then analyzed and scored using epifluorescence in the green channel, following a semiquantitative algorithm: 1-5 pneumococci per field in at least three fields corresponded to "+", 5-10 pneumococci per field to "++", and more than 10 pneumococci per field was scored as "+++". Negative samples had no pneumococci observed. Micrographs from positive specimens were obtained using the 60x and 100x objectives.

Staining and confocal analysis of human sputum. An aliquot of sputum sample (10 µl) was dropped onto a slide and air dry for ~20 min at room temperature. The sputum was then stained for 1 h with Spn-FLUO (20 µg/ml) and wheat germ agglutinin conjugated to Alexa-555 [(WGA), 5 µg/ml]. The stained specimen was washed three times with PBS, air-dried, and mounted with ProLong Diamond Antifade mounting medium containing DAPI (Molecular

Probes). Confocal micrographs were obtained using a Nikon C2 laser scanning confocal microscopy system and z-stacks micrographs were analyzed using the NIS Elements Basic Research software, version 4.30.01 build 1021. For 3D visualization, creation of animations, and quantification purposes, images were processed using the Imaris software 64x Version 10.1.0 (Oxford Instruments).

DNA extraction and quantitative PCR (qPCR). DNA was extracted as described earlier using a QIAamp DNA mini kit (Qiagen)[30, 36]. Bacterial density was quantified by qPCR reactions in a total 25 µl volume. Reactions contained 1x Platinum qPCR superMix (Invitrogen), 200 nm each of primers and probe, and 2.5 µl of purified DNA. The nucleotide sequence of primers and probe were published elsewhere[12]. No template controls (NTC) were run with each set of samples. qPCR reactions were carried out using a CFX96 Real-Time PCR Detection System (Bio-Rad). The following amplification parameters were utilized, 95°C for 2 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. qPCR standards using genomic DNA from reference strain TIGR4 (ATCC BAA-334) were run in parallel to construct a standard curve utilized to calculate genome equivalents (GenEq)/ml using the software Bio-Rad CFX manager. Standards DNA Preparation: Purified DNA was adjusted to a concentration of 1 ng/µl in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) and immediately stored at -80°C until use. Standards for quantification were prepared within an hour before reactions by serially diluting a 1 ng/µl aliquot in TE buffer to final concentrations of 100 pg/µl, 10 pg/µl, 1 pg/µl, 100 fg/µl, 50 fg/µl, and 5 fg/µl of pneumococcal DNA. Given the 2.1608 Mb genome size of TIGR4[20], these standards corresponded to $4.29x10^5$, $4.29x10^4$, $4.29x10^3$, $4.29x10^2$, $4.29x10^1$, $2.14x10^1$, or 2.14 GenEq,

respectively. Standards prepared using this protocol consistently achieved an efficiency greater than 90% throughout the study (data not shown).

Isolation and identification of *S. pneumoniae* strains. Nasopharyngeal specimens were thawed, vortexed for 15 s and 200 µl transferred to a 5 ml Todd-Hewitt broth (THY) containing 0.5% of yeast extract and 1 ml of rabbit serum (Gibco® by Life Technologies)[37]. This enriched culture was incubated for 6 h at 37°C in a 5% CO_2 atmosphere and then inoculated onto BAP and incubated for 18-24 h at 37°C in a 5% CO_2 atmosphere. Spn strains were isolated and identified using the optochin test (Remel) and bile solubility test as previously described[37].

Spn strains were isolated and identified from lower respiratory tract specimens including sputum, endotracheal aspirates, bronchoalveolar lavage fluids, bronchial washings, protected brush specimens, and lung aspirates, using standard methodologies[38]. Briefly, after Gram staining, the primary media including 5% Columbia sheep blood, Chocolate, and MacConkey agars (BD BBL™) were inoculated. Thioglycolate broth was employed for bronchial brush samples. The media were incubated for 18 to 24 h at 35-37°C in 5% CO_2, and cultures that remained negative after this period were re-incubated for another 24 h.

Pathogenic organisms were identified and susceptibility testing was performed only on significant growth, characterized by moderate to abundant colonies in the second or further quadrants of the plate, small numbers of a pathogen consistent with the predominant Gram-stain morphotype, and associated with inflammatory white blood cells, or colonies in the first quadrant if minimal or no other normal flora was present. Alpha-hemolytic, dry, or mucoid colonies resembling Spn strains were identified using Matrix Assisted Laser Desorption

Ionization Time-of-Flight (VITEK® MS) or VITEK® 2 Gram-Positive identification card (GP), and purity was confirmed with the optochin disc. The antibiotic sensitivity was determined using VITEK® 2 Gram-Positive Susceptibility Cards, and the manual D-test.

Statistical analysis. We performed one-way analysis of variance (ANOVA) followed by Dunnett's multiple-comparison test when more than two groups were compared or Student's t test to compare two groups, as indicated. All statistical analysis was performed using the software GraphPad Prism (version 8.3.1).

Results

***In vitro* assessment of fluorescently-labeled anti-Spn antibodies for detecting *S. pneumoniae* strains.** We first evaluated the ability of fluorescently-labeled antibodies to detect specific Spn strains. Antibodies targeting vaccine serotypes, or serogroups, were labeled as detailed in Material and Methods. In addition to their specific reactivity against corresponding serotypes/serogroups, the labeled antibodies did not exhibit cross reactivity against a panel of other serotypes (not shown). For instance, the anti-S4-A488 (green), or anti-S19-A555 (red) antibody specifically stained Spn serotype 4 or 19F, respectively, within five min of exposure as evaluated by fluorescence microscopy (Fig. 1A and not shown). High-resolution micrographs using confocal microscopy were obtained from S19F strain 4924 growing on a glass substratum (Fig. 1B).

We next evaluated the detection of Spn strains using fluorescently labeled antibodies in strains infecting *in vitro*-cultured human pharyngeal cells. Pharyngeal cells were infected for four h with strain D39 (serotype 2) or with a mixture of strains D39 and TIGR4 (serotype 4), and

subsequently stained with anti-S2-A555 or with a combination of anti-S2-A555 and anti-S4-A488. Cell nuclei were also stained with a fluorescent dye. Spn strains were identified in cells infected with a single serotype (Fig. 1C). Additionally, each individual Spn strain was detected on pharyngeal cells infected with the D39-TIGR4 mixture (Fig. 1D).

Detection of Spn vaccine strain serotype 19F in the mouse upper respiratory tract. A murine model of nasopharyngeal carriage was employed to assess the utility of fluorescent antibodies for detecting Spn strains. Eleven mice were intranasally inoculated with ~10^5 colony-forming units (CFU) of Spn strain EF3030, a serotype 19F strain commonly used in animal models of pneumococcal carriage[24, 39]. This inoculum was previously optimized to induce colonization levels comparable to those observed in the nasopharynx of children[33, 40].

Two days post-infection, nasopharyngeal tissue from the upper respiratory tract was collected and stored in paraformaldehyde or homogenized. An aliquot of the nasopharyngeal homogenate was subjected to serial dilution and plating to quantify the pneumococcal burden. All mice were colonized with a median bacterial load of 7.2x10^4 cfu/organ (interquartile range: 7.1x10^4 - 3.3x10^5) (Table 1). Subsequently, aliquots of the nasopharyngeal homogenates were subjected to pneumococcal detection assays. We employed an anti S19-A555 antibody, known to recognize strain serotype 19F EF3030[41], and Spn-FLUO antibody raised against 92 pneumococcal serotypes, including serotype 19F. Both antibodies detected pneumococci in 72% of the specimens (8/11) (Fig. 1E and Table 1). Detection of pneumococci was not achieved in nasopharyngeal homogenates with a bacterial density ≤7.1x10^3 cfu/organ (Fig. 1G and Table 1). Histological analysis of nasopharyngeal tissue revealed intracellular pneumococci within

goblet cells indicating a good performance of antibody-based detection at the tissue level (Fig. 1F).

Phenotypic and genotypic identification of *S. pneumoniae* in human nasopharyngeal specimens. For this initial proof-of-concept study, we selected fifty nasopharyngeal specimens from children from our previous studies[28, 30, 42] and were divided into two groups (N=25 each) as detailed in Table 2. In one group, containing nasopharyngeal specimens listed as 1 through 25, Spn strains were isolated and identified using both traditional and genomic methods. In the other group (i.e., nasopharyngeal specimens 26 through 50) Spn cultures were negative.

DNA was extracted from these nasopharyngeal samples and utilized as template in qPCR reactions targeting the species-specific *lytA* gene. Nasopharyngeal specimens 26 through 50 tested negative for Spn using *lytA*-PCR. As expected, *lytA*-PCR was positive for all nasopharyngeal specimens 1 to 25 (Table 2). The specimens were processed microscopically using fluorescently labeled antibodies, following the algorithm outlined in Figure 2A. Five distinct fields were examined within each preparation. The sensitivity of Spn-FLUO for detecting Spn strains in human nasopharyngeal specimens was 96% (24/25), while specificity was 100% as no Spn was detected in *lytA*-negative, culture-negative specimens. A typical microscopy finding from specimens containing abundant Spn (i.e., +++) is shown in Fig. 2C-D. The lowest bacterial density detected by fluorescent antibody staining was 1.61×10^4 GenEq/ml (Table 2 and Fig. 2B).

Detection and quantification of *Streptococcus pneumoniae* in mouse lung tissue during pneumonia. We next conducted a pre-clinical evaluation of Spn-FLUO for the detection of pneumococci in lung specimens using a murine model of pneumococcal pneumonia. Mice were infected with Spn strain TIGR4 and euthanized when moribund. Lungs were collected, homogenized, and the Spn bacterial load was determined by serial dilution and plating (Table 3). Lungs from mice infected with an isogenic capsule-deficient mutant (Δ*spxB*Δ*lctO*) that has a defect for colonization[43, 44] served as controls. As expected, all animals infected with TIGR4 exhibited a high lung colonization density of $1.18x10^7$ (interquartile range: $2.37x10^6$ - $1.12x10^8$) colony-forming units (CFU)/g, whereas those infected with the isogenic mutant displayed low colonization levels (Fig. 3A). Spn was detected in all lung specimens from TIGR4-infected animals at varying levels of positivity. In contrast, mutant-infected animals exhibited significantly lower bacterial burdens, with $<1x10^3$ cfu/g or no detectable bacteria (Fig. 3B, 3C and Table 3). Specimens with the highest density and positive Spn-FLUO detection were statistical different compared to those containing a lower burden of pneumococci (Fig. 3C). The highest positive reaction with Spn-FLUO was achieved in lungs from mice colonized with a median of $1.41x10^8$ CFU/g, which was statistically significant compared to groups with lower detection levels (Fig. 3B). Thus, Spn-FLUO demonstrated a strong correlation between fluorescence detection of pneumococci and bacterial load in a murine model of pneumococcal pneumonia, suggesting its potential as a rapid and sensitive diagnostic tool.

Detection of pneumococcal strains using Spn-FLUO in clinical specimens from patients with pneumococcal pneumonia. We subsequently evaluated the sensitivity of Spn-FLUO antibodies

in detecting pneumococcal strains within human specimens from patients with pneumococcal pneumonia. To assess this, we analyzed N=27 clinical specimens obtained from patients with microbiologically confirmed pneumococcal pneumonia, each yielding a pneumococcal isolate. Specimens comprised sputum and bronchioalveolar lavage fluid (Table 4). DNA was extracted from all 27 specimens, each of which yielded a positive *lytA*-based qPCR result, indicating varying bacterial loads expressed as genome equivalents per milliliter (GE/ml). Consistently, all specimens were also positive for *piaB* (data not shown).

Spn-FLUO identified the pneumococcal etiology in 25/27 specimens, resulting in percent positive agreement of 92.6%. Specimens with high pneumococcal detection per field using Spn-FLUO contained a median bacterial load of $1.13x10^8$ GE/ml by *lytA*-based qPCR (interquartile range: $4.57x10^7$ - $4.85x10^8$) (Fig. 4A and Table 4). Specimens with low-moderate (i.e., scored +, and ++) detection of Spn per field had a median bacteria load of $5.10x10^5$ GE/ml (interquartile range: $1.11x10^5$ - $2.96x10^6$), while the specimen with the lowest GE/ml that yielded a positive reaction with the Spn-FLUO antibodies contained $3.63x10^3$ GE/ml of pneumococcal DNA (Fig. 4A).

Representative images of Spn detected in sputum specimens are shown in Figure 4B-D. Fluorescence and bright-field microscopy revealed a heterogeneous mixture of epithelial cells, leukocytes, and bacteria resembling pneumococcal aggregates (Fig. 4B-D, arrows). While pneumococcal chains were also observed, these were less abundant than the bacterial aggregates. In a sputum specimen from a patient with pneumococcal pneumonia, additional bacteria were noted, although only pneumococci were stained by Spn-FLUO (Figure 4B-D,

arrowhead). In summary, Spn-FLUO detected Spn strains in 92.6% of clinical specimens from patients with pneumococcal pneumonia within 30 min.

Ultrastructural studies of *Streptococcus pneumoniae* in human sputum. Given the presence of abundant mucus and thick smears in some specimens, as well as the observation of large pneumococcal aggregates in unprocessed sputum, we performed high-resolution 3D confocal analysis of sputum specimens. Sputum was stained with Spn-FLUO, DAPI, and wheat germ agglutinin (WGA which binds to N-acetyl-D-glucosamine (GlcNAc) and sialic acid (SA) residues. GlcNAc/SA was utilized since sialic acid is a biomarker for mucin content[45]. A middle optical section of the XY, XZ (bottom panel), and YZ (side panel) focal planes revealed a large structure composed of aggregated pneumococci, isolated smaller aggregates, and pneumococcal chains (Fig. 5A and Video S1). An optical zoom revealed abundant DNA located adjacent to pneumococcal aggregates, suggesting the release from neighboring cells or cellular lysis (Fig. 5B). Orthogonal XZ and YZ sections demonstrated that the aggregates were embedded within the sputum (Fig. 5B, bottom panel). Pneumococci in closed proximity to cell nuclei, either in the process of capsule loss or already decapsulated (i.e., D-CPS), were observed in regions of the sputum resembling internalized bacteria (Fig. 5C).

We performed three-dimensional reconstruction of the capsule channel (green) from confocal z-stacks (Fig. 5D) and categorized pneumococci into two groups: those within aggregates (Fig. 5E) and those forming chains or dispersed within the preparation (Fig. 5F). Representative pneumococcal aggregates are shown in Fig. 5G. The area of these pneumococcal aggregates was significantly different compared to all other pneumococci (Fig.

5H). The median area of pneumococcal aggregates was 1336 μm^2 (interquartile range: 959 – 2108 μm^2) whereas the median area of pneumococcal chains and dispersed bacteria was 9.15 μm^2 (interquartile range: 3.6 – 14.3 μm^2) (Fig. 5G).

Further 3D analysis of orthogonal XY and XZ focal planes demonstrated that the GlcNAc/SA signal did not colocalize with pneumococcal aggregates but instead surrounded encapsulated pneumococci (Fig. 5I). Overall, the data revealed that pneumococcal aggregates embedded in sputum specimens are significantly larger than those in chain or dispersed forms, potentially providing a physical barrier shielding pneumococci from sputum components.

Discussion

In this study, we demonstrated the feasibility of fluorescent antibody-based microscopy for the rapid diagnosis of pneumococcal pneumonia. The entire process, from sample collection to final diagnosis, was completed within 30 min. Prompt identification of the causative agent is crucial in severe pneumonia, often influencing patient outcomes[9]. Spn-FLUO offers a valuable alternative for rapid diagnosis, particularly in cases where mortality remains high despite low antibiotic resistance rates, as observed with serotype 3 strains in Spain[46]. The rapid identification of the pneumococcus in clinical specimens allows for timely adjustment of empirical therapy, which is particularly important in severe cases. Although this technology requires a fluorescence microscope, the objective nature of the fluorescent signal from Spn strains makes fluorescence antibody-based detection suitable for resource-limited regions, as DNA extraction, reaction mixtures, and real-time systems are not necessary, and minimal training is required. Furthermore, clinical trials recruiting patients with pneumococcal

pneumonia can benefit from a swift decision on whether potential individuals with signs and symptoms of pneumococcal pneumonia can be included in the trial.

Despite significant advancements in technology for the detection of pathogens causing pneumonia, pneumococcal pneumonia diagnosis remains challenging[9]. The culture of lower respiratory tract specimens, while considered the gold standard, is often associated with delays and low sensitivity. Multiplexed PCR panels have demonstrated improved sensitivity to detect pathogens not recovered by culture, but they require substantial resources, specialized equipment, and highly trained personnel, with turnaround times of several hours[9, 10, 47]. Antigen detection assays, such as those targeting the pneumococcal capsule, offer the advantage of rapid turnaround time. However, their specificity to a single pathogen represents a limitation. Nonetheless, they can be a life-saving tool in critical situations.

To the best of our knowledge, no previous studies have investigated the ultrastructure of pneumococci in freshly expectorated human sputum from patients with pneumonia. The current study filled this gap by characterizing the unique structures formed by pneumococci in the sputum. These bacterial aggregates are large, with a median size of 1336 μm^2, and have not been observed invading the lungs of patients with pneumococcal pneumonia or in the lungs of mice infected with Spn strains. This population of pneumococci, which likely resides extracellularly on bronchi and bronchioles, may be formed to resist the innate and adaptive immune response. These aggregated extracellular pneumococci represent an important novel population that may be more resistant to antibiotics and antimicrobial peptides.

Our study has some limitations. Notably, Spn-FLUO exclusively recognizes encapsulated pneumococci, limiting its utility for detecting non-encapsulated strains. While the majority of

isolates express capsule, this limitation could hinder the detection of other non-encapsulated strains[48]. Additionally, studies evaluating Spn-FLUO sensitivity in both mouse lung specimens and human lung specimens from patients with pneumococcal pneumonia involved specimens from where strains were isolated in culture, suggesting a high bacterial load, later confirmed by qPCR assays. We did not assess the specificity of Spn-FLUO against a panel of Spn-negative human sputum samples or healthy subjects. Instead, as a surrogate, we utilized human nasopharyngeal specimens with a *lytA*-negative reaction and lung specimens from mice infected with a strain with a colonization defect and low capsule production. In both cases, specificity was 100%.

In summary, we have characterized a rapid method for detecting the pneumococcus in clinical specimens from patients with pneumonia. Using the fluorescent antibodies developed in this study, we have provided novel ultrastructural information regarding a previously uncharacterized population of pneumococcal aggregates. This study serves a dual purpose. First, antibody-based detection of pneumococci can be further developed to guide empirical therapy while awaiting culture results. Second, it fosters novel research into pneumococcal aggregates, which may serve as reservoirs for the pneumococcus.

List of abbreviations

Streptococcus pneumoniae: Spn

Fluorescent antibodies against the pneumococcal capsule: Spn-FLUO

Quantitative polymerase chain reaction: qPCR

Limit of Detection: LOD

Genome equivalents/milliliter: GenEq/ml

459 Square micrometer: μm^2

460 Minutes: min

461 Community-acquired pneumonia : CAP

462 Carbon dioxide: CO_2

463 Oxygen: O_2

464 Hours: h

465 Multiplex polymerase chain reaction: (m)PCR

466 Colony Forming Units: CFU

467 Colony forming units/gram: CFU/g

468 Wheat Germ Agglutinin: WGA

469 N-acetyl-D-glucosamine : GlcNAc

470 Sialic acid: SA

471 Blood agar plates: BAP

472 Todd Hewitt broth containing yeast extract: THY

473 Streptomycin: Str

474 Trimethoprim: Tmp

475 Tetracycline: Tet

476 Erythromycin: Ery

477 Microgram/milliliter: µg/ml

478 Phosphate Buffered Saline: PBS

479 Minimum Essential Medium: MEM

480 Fetal Bovine Serum: FBS

481 Paraformaldehyde: PFA

482 Bovine Serum Albumin: BSA

483 Micromole: µM

484 Institutional Animal Care and Use Committee: IACUC

485 National Science Foundation Animal Welfare Act: AWA

Institutional Review Board: IRB

University of Mississippi Medical Center: UMMC

World Health Organization: WHO

Nasopharyngeal: NP

Microliter: µl

Nanogram/microliter: ng/ µl

Megabase: Mb

Seconds: s

Declarations

Ethics approval

The research project "Mechanistic Studies of Broadly Reactive Antibodies for the Treatment, Diagnosis, and Prevention of Pneumococcal Infection" has been reviewed by the Institutional Review Board (IRB) of the University of Mississippi Medical Center (Federalwide Assurance FWA#00003630) and has been determined to be exempt from formal review. The IRB concluded that the project meets the criteria for exemption as outlined in the U. S. Department of Health and Human Services Regulations for the Protection of Human Subjects, 45 CFR 46.102(l) because this project does not research involving human subjects. As such, no additional ethical review was required.

All experiments involving animals were performed with prior approval of and in accordance with protocol 1584 which was reviewed and approved by the UMMC Animal Care Committee. UMMC laboratory animal facilities have been fully accredited by the American Association for Accreditation of Laboratory Animal Care. Procedures were performed according

509 to the institutional policies, Animal Welfare Act, NIH guidelines, and American Veterinary
510 Medical Association guidelines on euthanasia.

511

512 **Consent to participate**

513 N/A

514

515 **Consent for publication**

516 N/A

517

518 **Availability of data and materials**

519 All data generated or analyzed during this study are included in this published article (and its
520 supplementary information files) and are available from the corresponding author on
521 reasonable request. The materials such as software, protocols or reagents were specified in the
522 Material and Methods section.

523

524 **Competing interests**

525 The authors declare that they have no competing interests.

526

Funding

This study was supported in part by a grant from the National Institutes of Health (NIH; 5R21AI144571-03, R01AI173084-03 and 1R01AI175461-01A1) and by a grant from NIGMS through the Molecular Center of Health and Disease (1P20GM144041-01A1 7651). Studies of confocal microscopy, and histology, were supported by grants from the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health under Award Numbers P20GM121334 and P20GM104357. The content is solely the responsibility of the authors and does not necessarily represent the official view of the NIH.

Authors' contributions

A.G.J.V.- Formal analysis, Investigation, Supervision, Methodology, Project administration, Writing - review & editing.

M.F. - Formal analysis, Investigation.

M.C.- Investigation.

I.J.F.- Investigation.

P.S. - Investigation.

P.V.- Investigation.

C.F. L.- Investigation, Methodology, Writing- review & editing.

C.G. - Investigation, Methodology, Writing - review & editing.

W.D. - Investigation.

J.E.V. -Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Writing - original draft, Writing - review & editing.

All authors read and approved the final manuscript.

Acknowledgements. We thank Dr. Babek Alibayov from the University of Mississippi Medical Center (UMMC) for their assistance with labeling aliquots of Spn-FLUO, and Dr. Kenichi Takeshita, and Dr. Antonino Baez, also from UMMC, for their feedback on the manuscript. The authors also acknowledge the assistance of Dr. Fuminori Sakai from Emory University Rollins School of Public Health, currently at Pfizer Japan, for performing some qPCR assays.

References

1. Wahl, B. *et al.* Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. *Lancet Glob Health* **6**, e744-e757 (2018).

2. Weiser, J.N., Ferreira, D.M. & Paton, J.C. Streptococcus pneumoniae: transmission, colonization and invasion. *Nat Rev Microbiol* **16**, 355-367 (2018).

3. Musher, D.M. & Thorner, A.R. Community-acquired pneumonia. *N Engl J Med* **371**, 1619-1628 (2014).

4. Ganaie, F. *et al.* A New Pneumococcal Capsule Type, 10D, is the 100th Serotype and Has a Large cps Fragment from an Oral Streptococcus. *mBio* **11** (2020).

5. Brissac, T. *et al.* Capsule Promotes Intracellular Survival and Vascular Endothelial Cell Translocation during Invasive Pneumococcal Disease. *mBio* **12**, e0251621 (2021).

6. Hyams, C., Camberlein, E., Cohen, J.M., Bax, K. & Brown, J.S. The Streptococcus pneumoniae capsule inhibits complement activity and neutrophil phagocytosis by multiple mechanisms. *Infect Immun* **78**, 704-715 (2010).

7. Kim, J.O. *et al.* Relationship between cell surface carbohydrates and intrastrain variation on opsonophagocytosis of Streptococcus pneumoniae. *Infect Immun* **67**, 2327-2333 (1999).

8. Miller, J.M. *et al.* A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology. *Clin Infect Dis* **67**, e1-e94 (2018).

9. Pletz, M.W. *et al.* Unmet needs in pneumonia research: a comprehensive approach by the CAPNETZ study group. *Respir Res* **23**, 239 (2022).

10. Walker, A.M., Timbrook, T.T., Hommel, B. & Prinzi, A.M. Breaking Boundaries in Pneumonia Diagnostics: Transitioning from Tradition to Molecular Frontiers with Multiplex PCR. *Diagnostics (Basel)* **14** (2024).

11. Marimuthu, S., Damiano, R.B. & Wolf, L.A. Performance Characteristics of a Real-Time PCR Assay for Direct Detection of Streptococcus pneumoniae in Clinical Specimens. *J Mol Diagn* **26**, 552-562 (2024).

12. Carvalho Mda, G. *et al.* Evaluation and improvement of real-time PCR assays targeting lytA, ply, and psaA genes for detection of pneumococcal DNA. *J Clin Microbiol* **45**, 2460-2466 (2007).

13. Wyllie, A.L. *et al.* Streptococcus pneumoniae in saliva of Dutch primary school children. *PLoS One* **9**, e102045 (2014).

14. Tavares, D.A. *et al.* Identification of Streptococcus pneumoniae by a real-time PCR assay targeting SP2020. *Sci Rep* **9**, 3285 (2019).

15. Shkodenko, L.A., Mohamed, A.A., Ateiah, M., Rubel, M.S. & Koshel, E.I. A DAMP-Based Assay for Rapid and Affordable Diagnosis of Bacterial Meningitis Agents: Haemophilus influenzae, Neisseria meningitidis, and Streptococcus pneumoniae. *Int J Mol Sci* **25** (2024).

16. Gotts, J.E. *et al.* Clinically relevant model of pneumococcal pneumonia, ARDS, and nonpulmonary organ dysfunction in mice. *Am J Physiol Lung Cell Mol Physiol* **317**, L717-L736 (2019).

17. Lee, J.S., Giesler, D.L., Gellad, W.F. & Fine, M.J. Antibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia: A Systematic Review. *JAMA* **315**, 593-602 (2016).

18. Wu, X. *et al.* Effect of pneumococcal conjugate vaccine availability on Streptococcus pneumoniae infections and genetic recombination in Zhejiang, China from 2009 to 2019. *Emerg Microbes Infect* **11**, 606-615 (2022).

19. Viteri-Davila, C. *et al.* The Crisis of Macrolide Resistance in Pneumococci in Latin America. *Am J Trop Med Hyg* (2024).

20. Tettelin, H. *et al.* Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. *Science* **293**, 498-506 (2001).

21. Wu, X. *et al.* Interaction between Streptococcus pneumoniae and Staphylococcus aureus Generates (.)OH Radicals That Rapidly Kill Staphylococcus aureus Strains. *J Bacteriol* **201** (2019).

22. McDevitt, E. *et al.* Hydrogen Peroxide Production by Streptococcus pneumoniae Results in Alpha-hemolysis by Oxidation of Oxy-hemoglobin to Met-hemoglobin. *mSphere* **5** (2020).

23. Lanie, J.A. *et al.* Genome sequence of Avery's virulent serotype 2 strain D39 of Streptococcus pneumoniae and comparison with that of unencapsulated laboratory strain R6. *J Bacteriol* **189**, 38-51 (2007).

24. Junges, R., Maienschein-Cline, M., Morrison, D.A. & Petersen, F.C. Complete Genome Sequence of Streptococcus pneumoniae Serotype 19F Strain EF3030. *Microbiol Resour Announc* **8** (2019).

25. Wu, X. *et al.* Competitive Dominance within Biofilm Consortia Regulates the Relative Distribution of Pneumococcal Nasopharyngeal Density. *Appl Environ Microbiol* **83** (2017).

26. Wu, X. *et al.* Ultrastructural, metabolic and genetic characteristics of determinants facilitating the acquisition of macrolide resistance by Streptococcus pneumoniae. *Drug Resist Updat* **77**, 101138 (2024).

27. Alibayov, B. *et al.* Oxidative Reactions Catalyzed by Hydrogen Peroxide Produced by Streptococcus pneumoniae and Other Streptococci Cause the Release and Degradation of Heme from Hemoglobin. *Infect Immun* **90**, e0047122 (2022).

28. Sakai, F., Sonaty, G., Watson, D., Klugman, K.P. & Vidal, J.E. Development and characterization of a synthetic DNA, NUversa, to be used as a standard in quantitative polymerase chain reactions for molecular pneumococcal serotyping. *FEMS Microbiol Lett* **364** (2017).

29. Pholwat, S., Sakai, F., Turner, P., Vidal, J.E. & Houpt, E.R. Development of a TaqMan Array Card for Pneumococcal Serotyping on Isolates and Nasopharyngeal Samples. *J Clin Microbiol* **54**, 1842-1850 (2016).

30. Chien, Y.W. *et al.* Density interactions among Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus in the nasopharynx of young Peruvian children. *Pediatr Infect Dis J* **32**, 72-77 (2013).

31. Grijalva, C.G. *et al.* Cohort profile: The study of respiratory pathogens in Andean children. *Int J Epidemiol* **43**, 1021-1030 (2014).

32. Howard, L.M. *et al.* Association between nasopharyngeal colonization with multiple pneumococcal serotypes and total pneumococcal colonization density in young Peruvian children. *Int J Infect Dis* **134**, 248-255 (2023).

33. Nelson, K.N. *et al.* Dynamics of Colonization of Streptococcus pneumoniae Strains in Healthy Peruvian Children. *Open Forum Infect Dis* **5**, ofy039 (2018).

34. Satzke, C. *et al.* Standard method for detecting upper respiratory carriage of Streptococcus pneumoniae: updated recommendations from the World Health Organization Pneumococcal Carriage Working Group. *Vaccine* **32**, 165-179 (2013).

35. O'Brien, K.L. *et al.* Evaluation of a medium (STGG) for transport and optimal recovery of Streptococcus pneumoniae from nasopharyngeal secretions collected during field studies. *J Clin Microbiol* **39**, 1021-1024 (2001).

36. Sakai, F., Talekar, S.J., Klugman, K.P. & Vidal, J.E. Expression of Virulence-Related Genes in the Nasopharynx of Healthy Children. *PloS one* **8**, e67147 (2013).

37. Centers for Desease Control and Prevention & (CDC). Streptococcus pneumoniae carriage study protocol - nasopharyngeal (NP) swab processing.; 2010.

38. Leber, A.L. *Clinical microbiology procedures handbook*, 4th edition. edn. ASM Press: Washington, DC, 2016.

39. Scott, E.J., 2nd, Luke-Marshall, N.R., Campagnari, A.A. & Dyer, D.W. Draft Genome Sequence of Pediatric Otitis Media Isolate Streptococcus pneumoniae Strain EF3030, Which Forms In Vitro Biofilms That Closely Mimic In Vivo Biofilms. *Microbiol Resour Announc* **8** (2019).

40. Vidal, J.E. *et al.* Prophylactic inhibition of colonization by Streptococcus pneumoniae with the secondary bile acid metabolite deoxycholic acid. *Infect Immun*, IAI0046321 (2021).

41. Vidal, J.E. *et al.* Prophylactic Inhibition of Colonization by Streptococcus pneumoniae with the Secondary Bile Acid Metabolite Deoxycholic Acid. *Infect Immun* **89**, e0046321 (2021).

42. Hanke, C.R. *et al.* Bacterial Density, Serotype Distribution and Antibiotic Resistance of Pneumococcal Strains from the Nasopharynx of Peruvian Children Before and After Pneumococcal Conjugate Vaccine 7. *Pediatr Infect Dis J* **35**, 432-439 (2016).

43. Echlin, H., Frank, M., Rock, C. & Rosch, J.W. Role of the pyruvate metabolic network on carbohydrate metabolism and virulence in Streptococcus pneumoniae. *Mol Microbiol* **114**, 536-552 (2020).

44. Alibayov, B. *et al.* Oxidation of hemoglobin in the lung parenchyma facilitates the differentiation of pneumococci into encapsulated bacteria. *bioRxiv* (2023).

45. Esther, C.R., Jr. *et al.* Sialic acid-to-urea ratio as a measure of airway surface hydration. *Am J Physiol Lung Cell Mol Physiol* **312**, L398-L404 (2017).

46. Calvo-Silveria, S. *et al.* Evolution of invasive pneumococcal disease by serotype 3 in adults: a Spanish three-decade retrospective study. *Lancet Reg Health Eur* **41**, 100913 (2024).

47. Riccobono, E., Bussini, L., Giannella, M., Viale, P. & Rossolini, G.M. Rapid diagnostic tests in the management of pneumonia. *Expert Rev Mol Diagn* **22**, 49-60 (2022).

48. Keller, L.E., Robinson, D.A. & McDaniel, L.S. Nonencapsulated Streptococcus pneumoniae: Emergence and Pathogenesis. *mBio* **7**, e01792 (2016).

731 **Figure legends**



732

733 **Figure 1. *In vitro* and *in vivo* detection of pneumococci with fluorescently-labelled antibodies.**

734 Strain TIGR4 (A) was mixed with anti S4-A488 (green) antibody and observed under a

735 epifluorescence microscope within five minutes. (B) Spn serotype 19F strain 4924 was cultured

736 for four h in a 8-well slide and pneumococci attached to the substratum were stained with an

737 anti S19-A555 (red) antibody and the DNA was stained with DAPI. (C-D) Human pharyngeal cells

738 grown to confluence were inoculated with (C) strain D39 or (D) a mixture of strain D39 and

739 strain TIGR4 and incubated for four hours. D39 was stained with S2-A555 (red) and TIGR4 was

740 stained with S4-A488. In panel C, DNA was stained with TO-PRO-3, while in panel D, it was

741 stained with DAPI. (E-F) C57BL/6 mice (N=11) were intranasally inoculated with serotype 19F

742 strain EF3030. After 48 h, mice were euthanized, and the nasal bone was removed.

743 Nasopharyngeal tissue was collected, sectioned (~5 µm), or homogenized. Nasopharyngeal

744 homogenate (E) or tissue sections (F) were stained with DAPI and with an anti S19-A555

745 antibody. Arrows point out Spn. In panels B-F, micrographs were obtained by confocal

746 microscopy, and the projection of z-stacks is shown. (G) Nasopharyngeal homogenates were

diluted and plated to obtain the bacterial density. The density in the plot was grouped according to whether the samples yielded a positive reaction with Spn-FLUO or were not detected (ND). Student t test, $^{**}p$=0.01.



Figure 2. Detection of *S. pneumoniae* with Spn-FLUO in human specimens. (A) Detection algorithm for the identification of Spn in clinical specimens. Five fields were screened using the 60x objective, and a specimen was scored positive when ≥1 to <5 (+), ≥5 to <10 (++), or ≥10 (+++) pneumococci were observed in at least three fields. This algorithm was chosen to ensure the reliable detection of Spn while minimizing the risk of false positives. (B) The density of *S. pneumoniae* in nasopharyngeal specimens that yielded a positive reaction with Spn-FLUO was categorized depending on the semiquantitative algorithm. Data are presented as mean ± SD.

758 Differences in bacterial density were determined using one-way ANOVA followed by Dunnett's
759 multiple comparisons test. ns=no significant difference. (C-D) Sputum specimen stained with
760 Spn-FLUO and observed under (C) bright field and (D) epifluorescence in the green channel.
761 Arrows point out Spn identified by Spn-FLUO.
762



763

764 **Figure 3. Detection of *S. pneumoniae* with Spn-FLUO in mouse lung specimens.** Balb/c mice
765 were intranasally inoculated with strain TIGR4 or isogenic mutant Δ*spxB*Δ*lctO* and euthanized
766 when deemed moribund, or after 96 h post-infection. Lungs were collected and homogenized.
767 (A) Lung homogenates were diluted and plated to obtain the bacterial density. (B) Aliquots of
768 lung homogenate were stained with Spn-FLUO and scored for the presence of pneumococci.
769 Micrographs were obtained with a fluorescence microscope in the green channel. The top panel
770 shows a representative specimen scored "+" with arrows pointing out *S. pneumoniae*, while the
771 bottom panel shows a representative specimen that scored "+++". (C) The density in the

graphic was grouped according to the semiquantitative detection of *S. pneumoniae* with Spn-FLUO. Statistical significance of differences in bacterial density were determined using Student's t-test (A) or one-way ANOVA followed by Dunnett's multiple comparisons test (C). *p=0.027, **p=.0088, ***p=0.0007.



Figure 4. Detection of *S. pneumoniae* with Spn-FLUO in human sputum. (A) Aliquots of sputum were DNA extracted and used as templates in qPCR reactions targeting the *lytA* gene. Other aliquots were stained with Spn-FLUO, and the presence of *S. pneumoniae* was scored. The

graphic shows the pneumococcal genome equivalent (GenEq)/ml in all samples, categorized as low (scored +), medium (scored ++), or high (scored +++). Statistical significance of differences in bacterial density was assessed using the Student's t-test. ns=no significant difference. (B-D) Sputum specimens stained with Spn-FLUO and observed under (B) epifluorescence in the green channel or (C) bright field. Panel (D) shows the merged epifluorescence and bright field channels. Arrows point out *S. pneumoniae* identified by Spn-FLUO, while arrowheads signal staphylococcus-like microcolonies, which were not stained by Spn-FLUO but were observed in the bright field channels.



Figure 5. Ultrastructural analysis of *S. pneumoniae* in human sputum. Sputum specimens were stained with Spn-FLUO (green), wheat germ agglutinin (WGA) labeled with Alexa 555 (red), and DNA was stained with DAPI (blue). Preparations were analyzed by confocal microscopy. Panel (A) shows middle XY, XZ (bottom), and YZ (side) optical sections. The white inset indicates an optical zoom shown in panel (B), while the yellow inset indicates the region shown in panel (C). The bottom panels in (B and C) show orthogonal XZ and YZ sections. Decapsulated pneumococci (D-CPS) are indicated by the arrows. (D-F) A mask was created in the green channel (D) to

analyze the 3D structure of the pneumococcal (E) aggregate or (F) dispersed pneumococci. (G) Representative 3D images of aggregated pneumococci across the sputum specimen, showcasing their size, shape, and spatial distribution within the sputum. (H) The area of those aggregate pneumococci and that of dispersed bacteria was plotted. Student's t-test was performed to assess statistical significance, ****$p<0.0001$. (I) Orthogonal XY and YZ sections were created using the green (Spn-FLUO) and the red channel (WGA). WGA binds acetyl glucosamine and sialic acid residues (GlcNAc/SA). The top panel shows the masked green channel representing the area of the pneumococcal aggregate. The pneumococcal aggregate was removed from the middle panel to reveal the hollow spaces occupied by bacteria embedded in the sputum. The bottom panel shows the non-masked green channel and the red channel. All analyses were performed using the Imaris software.

Table 1. Detection of pneumococci using Spn-FLUO in the upper respiratory tract of mice.

Mouse nasopharynx	Density (cfu/organ)	Spn-FLUO*	S19-A555*
MN-1	$7.1x10^3$	ND	ND
MN-2	$3.27x10^5$	+	+
MN-3	$4.93x10^5$	+	+
MN-4	$1.4x10^4$	+	+
MN-5	$1.47x10^5$	+	+
MN-6	$4.83x10^5$	+	+
MN-7	$1.0x10^3$	ND	ND
MN-8	$4.5x10^3$	ND	ND
MN-9	$7.2x10^4$	+	+
MN-10	$3.07x10^4$	+	+
MN-11	$2.09x10^5$	+	+

***ND=not detected.**

+, up to five pneumococci per field in at least three fields of five observed using the 60x objective.

816 **Table 2. Detection of Spn in nasopharyngeal specimens from children with Spn-**
817 **FLUO.**
818

Nasopharyngeal specimen	qPCR (GenEq/ml) [#]	Spn-FLUO*
HN-1	5.73E+05	+++
HN-2	1.67E+06	+++
HN-3	1.61E+04	+
HN-4	2.60E+06	++
HN-5	1.46E+04	++
HN-6	4.47E+06	++
HN-7	1.20E+06	+++
HN-8	1.49E+05	++
HN-9	4.70E+05	++
HN-10	2.72E+05	+++
HN-11	1.75E+04	ND
HN-12	1.51E+04	++
HN-13	1.26E+06	+++
HN-14	5.83E+05	++
HN-15	1.08E+05	+++
HN-16	1.87E+04	++
HN-17	8.65E+05	++
HN-18	2.92E+06	+++
HN-19	3.81E+05	+
HN-20	1.67E+05	++
HN-21	4.18E+05	++
HN-22	1.08E+05	+
HN-23	1.12E+05	+
HN-24	7.64E+06	++
HN-25	8.88E+06	++
HN-26 to HN-50	Negative	Negative

819 [#]*lytA*-based qPCR assay. ND=not detected.

820

821

822

823 Table 3. Detection of pneumococci using Spn-FLUO in the lung of mice.

Mouse (strain)	Density (cfu/ml)	Spn-FLUO
ML-1 (TIGR4)	6.25E+07	+++
ML-2 (TIGR4)	2.39E+08	+++
ML-3 (TIGR4)	1.39E+04	+
ML-4 (TIGR4)	2.38E+06	++
ML-5 (TIGR4)	1.09E+08	+++
ML-6 (TIGR4)	4.23E+05	+
ML-7 (Δ*spxB*Δ*lctO*)	5.28E+03	ND
ML-8 (Δ*spxB*Δ*lctO*)	4.03E+02	ND
ML-9 (TIGR4)	2.35E+06	+
ML-10 (TIGR4)	3.60E+06	+
ML-11 (TIGR4)	7.40E+06	+
ML-12 (Δ*spxB*Δ*lctO*)	0.00E+00	ND
ML-13 (Δ*spxB*Δ*lctO*)	0.00E+00	ND
ML-14 (TIGR4)	1.21E+08	+++
ML-15 (TIGR4)	1.41E+08	+++
ML-16 (TIGR4)	1.62E+07	+++
ML-18 (TIGR4)	2.18E+07	+++
ML-19 (TIGR4)	3.64E+06	++

824

825

826

827

828

829

830

831

832

833

834

835 **Table 4. Detection of Spn in culture-positive specimen from patients with pneumococcal pneumonia**
836 **using Spn-FLUO.**

Specimen	ID	Specimen	qPCR (GE/ml)*	Spn-FLUO
HL1	082W	Sputum	$3.25x10^{6}$	+
HL2	U019	BAL[&] (endotracheal Tube)	$5.45x10^{7}$	+++
HL3	U0134	Sputum	$6.16x10^{5}$	+
HL4	U146	Sputum	$5.10x10^{5}$	+
HL5	U265	Sputum	$3.63x10^{3}$	+
HL6	U2275	BAL (endotracheal Tube)	ND	+++
HL7	U6831	BAL (endotracheal Tube)	$7.29x10^{9}$	+
HL8	U077	Sputum	$2.73x10^{5}$	+
HL9	U097	Sputum	$1.84x10^{5}$	+
HL10	U260	Sputum	$1.81x10^{6}$	+
HL11	U227.46	BAL (endotracheal Tube)	$4.85x10^{8}$	+++
HL12	U080	Sputum	$1.10x10^{7}$	+
HL13	U081	Sputum	$1.31x10^{7}$	++++
HL14	U081-W	Sputum	$7.54x10^{4}$	+
HL15	U220	Sputum	$2.60x10^{5}$	+
HL16	U766	Sputum	$6.36x10^{5}$	-
HL17	U156	Sputum	$7.56x10^{5}$	+
HL18	U209	Sputum	$2.67x10^{6}$	+
HL19	U210	Sputum	$5.32x10^{4}$	-
HL20	U501	Sputum	$3.95x10^{4}$	++
HL21	UC1	Sputum	$5.06x10^{7}$	++
HL22	UC2	Throat swab	$1.48.x10^{5}$	++
HL23	UC3	Throat swab	$1.57x10^{4}$	+
HL24	UC4	Sputum	$4.57x10^{7}$	++++
HL25	UC4	Endotracheal aspirate	$1.13x10^{8}$	++++
HL26	UC5	BAL (endotracheal tube)	$3.84x10^{8}$	+++
HL27	UE1	BAL (endotracheal tube)	$8.19x10^{6}$	++

837 *Genome equivalent/ml; [&]Bronchoalveolar lavage,


A
B
5 um
C
D
E
DAPI Spn
Spn
Spn
F
BF DAPI Spn
BF DAPI Spn
Spn
G
**
Density [cfu/g (log10)]
6
5
4
3
Spn-FLUO
ND


A
60x
1
2
3
4
5


B
ns
ns
Density [cfu/ml (log10)]
7
6
5
4
3
+
++
+++


C
Spn
Spn
Bright field


D
Spn
Spn
Spn-FLUO


A
***
Density [cfu/g (log10)]
9
8
7
6
5
4
3
WT
Mutant
B
Spn-FLOU +
Spn-FLUO +++
C
**
ns
*
Density [cfu/g (log10)]
9
8
7
6
5
4
+
++
+++
Spn detection


A
ns
GenEq/ml (log10)
10
9
8
7
6
5
4
3
2
Spn-Fluo
Moderate
Abundant
B
Spn-FLUO
10 µm
C
Bright field
D
MERGED


A
5 µm
B
2 µm
C
D-CPS
D-CPS
2 µm
D-CPS
D
E
8 µm
F
8 µm
H
****
Area [µm2 (log10)]
4
3
2
1
0
Aggregate
Disperse
I
Spn GlcNAc/SA
7 µm
7 µm
7 µm
G
3 µm
2 µm
3 µm
5 µm